Your browser doesn't support javascript.
loading
Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland
Silvia Stringhini; Ania Wisniak; Giovanni Piumatti; Andrew S Azman; Stephen A Lauer; Helene Baysson; David De Ridder; Dusan Petrovic; Stephanie Schrempft; Kailing Marcus; Isabelle Arm-Vernez; Sabine Yerly; Olivia Keiser; Samia Hurst; Klara Posfay-Barbe; Didier Trono; Didier Pittet; Laurent Getaz; Francois Chappuis; Isabella Eckerle; Nicolas Vuilleumier; Benjamin Meyer; Antoine Flahault; Laurent Kaiser; Idris Guessous.
Afiliação
  • Silvia Stringhini; Division of Primary Care, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland; University Centre fo
  • Ania Wisniak; Institute of Global Health, University of Geneva, Geneva, Switzerland
  • Giovanni Piumatti; Geneva University Hospitals
  • Andrew S Azman; Johns Hopkins University
  • Stephen A Lauer; Johns Hopkins University
  • Helene Baysson; University of Geneva
  • David De Ridder; University of Geneva
  • Dusan Petrovic; Geneva University Hospitals
  • Stephanie Schrempft; Geneva University Hospitals
  • Kailing Marcus; Geneva University Hospitals
  • Isabelle Arm-Vernez; Geneva Center for Emerging Viral Diseases and Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
  • Sabine Yerly; Geneva University Hospitals
  • Olivia Keiser; Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Samia Hurst; Institut Ethique, Histoire, Humanites, University of Geneva, Geneva, Switzerland
  • Klara Posfay-Barbe; Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Didier Trono; School of Life Sciences, Ecole Polytechnique Federale de Lausanne (EPFL), Lausanne, Switzerland
  • Didier Pittet; Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
  • Laurent Getaz; Division of Primary Care, Geneva University Hospitals, Geneva, Switzerland
  • Francois Chappuis; Division of Primary Care, Geneva University Hospitals, Geneva, Switzerland
  • Isabella Eckerle; Geneva Center for Emerging Viral Diseases and Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
  • Nicolas Vuilleumier; Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
  • Benjamin Meyer; University of Geneva
  • Antoine Flahault; Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Laurent Kaiser; Geneva Center for Emerging Viral Diseases and Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
  • Idris Guessous; Division of Primary Care, Geneva University Hospitals, Geneva, Switzerland
Preprint em Inglês | medRxiv | ID: ppmedrxiv-20088898
ABSTRACT
BackgroundAssessing the burden of COVID-19 based on medically-attended case counts is suboptimal given its reliance on testing strategy, changing case definitions and the wide spectrum of disease presentation. Population-based serosurveys provide one avenue for estimating infection rates and monitoring the progression of the epidemic, overcoming many of these limitations. MethodsTaking advantage of a pool of adult participants from population-representative surveys conducted in Geneva, Switzerland, we implemented a study consisting of 8 weekly serosurveys among these participants and their household members older than 5 years. We tested each participant for anti-SARS-CoV-2-IgG antibodies using a commercially available enzyme-linked immunosorbent assay (Euroimmun AG, Lubeck, Germany). We estimated seroprevalence using a Bayesian regression model taking into account test performance and adjusting for the age and sex of Genevas population. ResultsIn the first three weeks, we enrolled 1335 participants coming from 633 households, with 16% <20 years of age and 53.6% female, a distribution similar to that of Geneva. In the first week, we estimated a seroprevalence of 3.1% (95% CI 0.2-5.99, n=343). This increased to 6.1% (95% CI 2.69.33, n=416) in the second, and to 9.7% (95% CI 6.1-13.11, n=576) in the third week. We found that 5-19 year-olds (6.0%, 95% CI 2.3-10.2%) had similar seroprevalence to 20-49 year olds (8.5%, 95%CI 4.99-11.7), while significantly lower seroprevalence was observed among those 50 and older (3.7%, 95% CI 0.99-6.0, p=0.0008). InterpretationAssuming that the presence of IgG antibodies is at least in the short-term associated with immunity, these results highlight that the epidemic is far from burning out simply due to herd immunity. Further, no differences in seroprevalence between children and middle age adults are observed. These results must be considered as Switzerland and the world look towards easing restrictions aimed at curbing transmission.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo observacional Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo observacional Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
...